Synthetic Design Lab

Synthetic Design Lab is at the forefront of developing next-generation Antibody-Drug Conjugates (ADCs) aimed at treating various cancer indications. The company leverages a novel SYNTHBODY therapeutic platform, emphasizing a deep understanding of human biology to create more effective therapies. By focusing on human data over animal models, Synthetic Design Lab aims to deliver on the full potential of ADCs. The company primarily serves the oncology market, targeting patients in need of advanced cancer treatments. Its business model revolves around the development and commercialization of targeted cancer therapies, potentially generating revenue through partnerships, licensing, and direct sales of its therapeutic solutions. The company was founded by Dr. Chen, a pioneer in cancer immunotherapy and protein engineering, who brings extensive experience from his tenure at Genentech and IGM Biosciences. Keywords: ADC, cancer, SYNTHBODY, human biology, oncology, therapeutic platform, immunotherapy, protein engineering, targeted therapies, commercialization.